Park Avenue Securities LLC Has $8.75 Million Holdings in Gilead Sciences, Inc. $GILD

Park Avenue Securities LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 78,816 shares of the biopharmaceutical company’s stock after buying an additional 4,088 shares during the quarter. Park Avenue Securities LLC’s holdings in Gilead Sciences were worth $8,749,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC grew its position in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $27,000. Howard Hughes Medical Institute bought a new position in Gilead Sciences during the second quarter worth about $30,000. Putney Financial Group LLC grew its holdings in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the period. Finally, Kilter Group LLC acquired a new position in Gilead Sciences during the second quarter worth approximately $33,000. 83.67% of the stock is owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: UBS assigns a Buy rating and $145 price target, citing PrEP-led growth, easing HIV overhangs and pipeline upside as reasons to support a re-rating into 2027. Read More.
• Positive Sentiment: Citigroup raised its price target to $140 and kept a Buy rating, signaling analyst conviction that shares have meaningful upside from current levels. Read More.
• Positive Sentiment: Zacks highlights Gilead as a strong momentum stock based on its style scores, reinforcing the technical/quantitative case that investors may be rotating into the shares. Read More.
• Positive Sentiment: Gilead announced a research collaboration with OncoNano to test ON-BOARD™ encapsulation on a Gilead drug candidate — a partnership that could enhance delivery/stability and add optionality to the pipeline if the work advances. Read More.
• Neutral Sentiment: An article from Kalkine Media discusses Gilead in the context of Nasdaq‑100 and biopharma index dynamics; index inclusion/weighting stories can drive passive flows but the direct impact is uncertain. Read More.
• Neutral Sentiment: Yahoo Finance and MSN ran pieces assessing Gilead’s recent share momentum and post‑Q3 positioning; these are broad-market/valuation reads that inform sentiment but don’t convey new firm-level catalysts. Read More. Read More.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 price objective on shares of Gilead Sciences in a research report on Friday, October 31st. Royal Bank Of Canada boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. BMO Capital Markets set a $135.00 price target on Gilead Sciences in a report on Tuesday, November 25th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Finally, Sanford C. Bernstein set a $135.00 price objective on shares of Gilead Sciences and gave the company an “outperform” rating in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $133.20.

Gilead Sciences Stock Performance

GILD opened at $124.35 on Thursday. The business has a fifty day simple moving average of $123.19 and a 200 day simple moving average of $117.39. The company has a market capitalization of $154.28 billion, a PE ratio of 19.28, a price-to-earnings-growth ratio of 0.64 and a beta of 0.33. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter last year, the business earned $2.02 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s payout ratio is 48.99%.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $70,740,911.34. The trade was a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 136,257 shares of company stock worth $16,855,192. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.